DermTech Planning to Pursue LDT Path for Melanoma Test Using OpenArray qPCR | GenomeWeb

DermTech announced this week that it has raised $5.6 million in a Series B financing round, which it will use to commercialize its melanoma detection test using Life Technologies' OpenArray quantitative real-time PCR system and to establish a CLIA-certified lab facility in which to offer the assay.

The company has spent several years developing a melanoma identification test, which measures the expression of multiple gene targets in RNA extracted from skin samples collected using custom adhesive strips that non-invasively lift cells from suspicious lesions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: epigenetic contributors to type 1 diabetes, assembly algorithm to detect structural variations, and more.

The Financial Times looks into how sequencing is moving into the clinic.

Mitochondrial replacement therapy may soon be occurring in the UK, according to the Guardian.

The US House of Representatives has passed the latest version of the 21st Century Cures Act.